Predicted magnitude of in vivo P450 inhibition (CLi/CLi′) by different combinations of fluoxetine and norfluoxetine enantiomers using the additive (eq. 8) and the inhibitor-inhibitor interaction (eq. 9) models
| CYP2C19 | CYP3A4 | |||
|---|---|---|---|---|
| Additive | Inhibitor-Inhibitor Interaction | Additive | Inhibitor-Inhibitor Interaction | |
| (R)- and (S)-Fluoxetine | 8 | 8 | 1.5 | 1.5 |
| (R)- and (S)-Norfluoxetine | 13 | 13 | 2.1 | 2.1 |
| (R)-Enantiomers | 10 | 10 | 2.1 | 2.1 |
| (S)-Enantiomers | 12 | 12 | 1.5 | 1.5 |
| All enantiomers | 20 | 20 | 2.6 | 2.5 |